{"title":"Fondaparinux sodium combined with conventional therapy improves subchorionic hematoma with protein S deficiency.","authors":"Yan Tan, Zhenjiao Yan, Minhong Chen, Yinglan Wang","doi":"10.3233/THC-241035","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Fondaparinux sodium can prevent and treat acute illnesses and venous thromboembolism in patients undergoing surgery. At present, no studies have reported on treating subchorionic hematoma combined with protein S deficiency using fondaparinux sodium.</p><p><strong>Objective: </strong>To investigate the clinical efficacy of fondaparinux sodium in the treatment of patients with subchorionic hematoma combined with protein S deficiency.</p><p><strong>Methods: </strong>This single-center, open-ended, and prospective study enrolled 78 patients with subchorionic hematoma and protein S deficiency. They were randomly assigned to the treatment and control groups. The control group received conventional treatment, and the observation group received subepithelial injections of fondaparinux sodium (2.5 mg/day) based on conventional treatment. After 30 days of continuous treatment, the hematoma was evaluated by ultrasonography.</p><p><strong>Results: </strong>After treatment with fondaparinux sodium, a significant improvement in subchorionic hematoma was observed in the observation group compared with that in the control group (p< 0.05). A substantial improvement in prothrombin time and activated partial thromboplastin time was observed in the observation group after fondaparinux sodium treatment (p< 0.05). Furthermore, after fondaparinux sodium treatment, the duration of hematoma maintenance and incidence of adverse pregnancy outcomes were significantly reduced in the observation group compared with that in the control group (p< 0.05).</p><p><strong>Conclusion: </strong>With a favorable safety profile, fondaparinux sodium is effective in treating subchorionic hematoma combined with protein S deficiency. The results provide new ideas and methods for treating this disease, which is worthy of further promotion and application in clinical practice.</p>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3233/THC-241035","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Fondaparinux sodium can prevent and treat acute illnesses and venous thromboembolism in patients undergoing surgery. At present, no studies have reported on treating subchorionic hematoma combined with protein S deficiency using fondaparinux sodium.
Objective: To investigate the clinical efficacy of fondaparinux sodium in the treatment of patients with subchorionic hematoma combined with protein S deficiency.
Methods: This single-center, open-ended, and prospective study enrolled 78 patients with subchorionic hematoma and protein S deficiency. They were randomly assigned to the treatment and control groups. The control group received conventional treatment, and the observation group received subepithelial injections of fondaparinux sodium (2.5 mg/day) based on conventional treatment. After 30 days of continuous treatment, the hematoma was evaluated by ultrasonography.
Results: After treatment with fondaparinux sodium, a significant improvement in subchorionic hematoma was observed in the observation group compared with that in the control group (p< 0.05). A substantial improvement in prothrombin time and activated partial thromboplastin time was observed in the observation group after fondaparinux sodium treatment (p< 0.05). Furthermore, after fondaparinux sodium treatment, the duration of hematoma maintenance and incidence of adverse pregnancy outcomes were significantly reduced in the observation group compared with that in the control group (p< 0.05).
Conclusion: With a favorable safety profile, fondaparinux sodium is effective in treating subchorionic hematoma combined with protein S deficiency. The results provide new ideas and methods for treating this disease, which is worthy of further promotion and application in clinical practice.
背景：磺达肝癸钠可以预防和治疗手术患者的急性疾病和静脉血栓栓塞。目前，还没有关于使用磺达肝癸钠治疗绒毛膜下血肿合并蛋白 S 缺乏症的研究报道：探讨磺达肝癸钠治疗绒毛膜下血肿合并蛋白 S 缺乏症患者的临床疗效：这项单中心、开放性、前瞻性研究共纳入了 78 例绒毛膜下血肿合并蛋白 S 缺乏症患者。他们被随机分配到治疗组和对照组。对照组接受常规治疗，观察组在常规治疗的基础上接受磺达肝癸钠皮下注射（2.5 毫克/天）。连续治疗 30 天后，通过超声波检查评估血肿情况：结果：经磺达肝癸钠治疗后，观察组绒毛膜下血肿较对照组明显改善（P< 0.05）。在使用磺达肝癸钠治疗后，观察组的凝血酶原时间和活化部分凝血活酶时间均有明显改善（p< 0.05）。此外，与对照组相比，观察组在接受磺达肝癸钠治疗后，血肿维持时间和不良妊娠结局的发生率明显减少（P< 0.05）：结论：磺达肝癸钠治疗绒毛膜下血肿合并蛋白S缺乏症具有良好的安全性。结论：磺达肝癸钠治疗绒毛膜下血肿合并蛋白 S 缺乏症具有良好的安全性，为治疗该病提供了新的思路和方法，值得在临床上进一步推广和应用。
期刊介绍：
Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance.
Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
